Oncology · ChemotherapyRegulatory Approvalregulatorynear-term

FDA Grants AP Status for Methotrexate Sodium ANDA081099 by Barr

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/20/2026, 12:33:00 PM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval status for Barr's Methotrexate Sodium could significantly impact the competitive landscape in the oncology market. Pharma strategy teams should closely monitor Barr's market entry and pricing strategies to assess potential shifts in market dynamics. Regulatory context from FDA (FDA AP — METHOTREXATE SODIUM (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and pricing strategies for methotrexate products. The strongest clinical anchor is Genetic Studies of Chronic Active Epstein-Barr Disease (ClinicalTrials.gov), entity match (barr). In Oncology · Chemotherapy, 7 regulatory and 4 competitive items passed relevance filtering for Barr.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for Datopotamab Deruxtecan Supplement. This approval may enhance Barr's position in the oncology market, particularly in the generic segment for chemotherapy agents.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — METHOTREXATE SODIUM (ORIG) (FDA). Entity match (methotrexate sodium); Regulatory pathway relevance (nda). The approval indicates a successful regulatory pathway for Barr, which may influence future submissions and approvals for similar products in the oncology space.

Key Risks

Elevated medium regulatory exposure for Barr could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This approval may lead to increased competition in the generic chemotherapy segment, potentially affecting pricing and market share for existing methotrexate products.
Upside for Barr may improve if Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on market dynamics and pricing strategies for methotrexate products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and potential pricing strategies from Barr following this approval.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METHOTREXATE SODIUM (ORIG)
FDAhigh relevance
Entity match (methotrexate sodium); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM PRESERVATIVE FREE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — HEPARIN SODIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SODIUM BICARBONATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govhigh relevance
Entity match (barr)
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Electroacupuncture and Exercise for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Datopotamab Deruxtecan Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Hybreza Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Afatinib Dimaleate ANDA210750
Humanexa Signalsmedium relevance
Moderate corpus alignment

Barriers to satisfactory primary care contacts for Swedish cancer survivors: a cross-sectional survey.
PubMedhigh relevance
Entity match (barr)
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedhigh relevance
Entity match (barr)
FDA document
View source
Progress toward an Epstein-Barr virus vaccine.
PubMedhigh relevance
Entity match (barr)
FDA document
View source
Low-intensity pulsed ultrasound combined with microbubbles enhances amphotericin B delivery across the blood-brain barrier for improved therapy of cryptococcal meningitis.
PubMedhigh relevance
Entity match (barr)
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Barr
Methotrexate Sodium

Commercial impact

medium

This approval may lead to increased competition in the generic chemotherapy segment, potentially affecting pricing and market share for existing methotrexate products.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Barr, which may influence future submissions and approvals for similar products in the oncology space.

What to watch

Monitor market entry timelines and potential pricing strategies from Barr following this approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.